viewValeo Pharma Inc.

Valeo Pharma starts commercialization process of antitumor agent Yondelis in Canada

CEO Steve Saviuk called the treatment a “recognized global standard of care” in the fight against soft tissue sarcoma

Valeo Pharma Inc. -
Yondelis is a novel, synthetically produced agent isolated from Ecteinascidia turbinata, a type of sea squirt

Valeo Pharma Inc (CSE:VPH) revealed it has started commercialization of its new antitumor agent Yondelis in Canada.

The milestone follows Valeo’s receipt of a Notice of Compliance from Health Canada that authorized the transfer of the commercial rights of Yondelis, a novel, synthetically produced agent isolated from Ecteinascidia turbinata, a type of sea squirt.

The treatment is currently approved in Canada for patients with metastatic liposarcoma or leiomyosarcoma after traditional chemotherapy. It is also approved, in combination with chemotherapy drug Caelyx for second line treatment of patients with ovarian cancer. 

READ: GlaxoSmithKline receives green light for bone marrow cancer drug

Calling the drug a “recognized global standard of care” in dealing with soft tissue sarcoma, Valeo CEO Steve Saviuk told shareholders that the firm is aiming to expand awareness of its benefits and availability across Canada.

"The commercialization of Yondelis is the second of four products we plan on launching this summer,” Saviuk said in a statement.

“These launches, as well as the anticipated early fall approval of Redesca, underline our commitment to provide Canadian health care professionals and patients with important  therapeutics.”

Yondelis is manufactured by Spanish firm PharmaMar SA, which is based in Madrid.

Kirkland, Quebec-based Valeo Pharma is a specialty pharmaceutical company that commercializes innovative prescription products in Canada with a focus on neurodegenerative diseases, oncology and hospital specialty products.


Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Valeo Pharma Inc.

Price: 1.41 CAD

Market: CSE
Market Cap: $81.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Touchstone Exploration Shareholder Q&A

Touchstone Exploration Inc's (LON:TXP) Paul Baay joins Proactive London's Katie Pilbeam to answer questions from shareholders. Following Baay's live presentation at the Proactive One2One Investment Forum, shareholders were given the chance to put forward all of their queries. Baay runs...

4 hours, 6 minutes ago

2 min read